1. Home
  2. MHO vs SUPN Comparison

MHO vs SUPN Comparison

Compare MHO & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MHO

M/I Homes Inc.

HOLD

Current Price

$127.62

Market Cap

3.5B

ML Signal

HOLD

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$49.53

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MHO
SUPN
Founded
1976
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
2.9B
IPO Year
1986
2012

Fundamental Metrics

Financial Performance
Metric
MHO
SUPN
Price
$127.62
$49.53
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$153.00
$61.60
AVG Volume (30 Days)
188.8K
609.8K
Earning Date
01-28-2026
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
17.05
N/A
Revenue
$4,475,753,000.00
$681,539,000.00
Revenue This Year
N/A
$8.32
Revenue Next Year
N/A
$23.36
P/E Ratio
$7.50
N/A
Revenue Growth
4.77
4.54
52 Week Low
$100.22
$29.16
52 Week High
$158.92
$57.65

Technical Indicators

Market Signals
Indicator
MHO
SUPN
Relative Strength Index (RSI) 40.63 52.86
Support Level $127.43 $51.01
Resistance Level $129.89 $52.30
Average True Range (ATR) 2.95 1.38
MACD -0.48 0.05
Stochastic Oscillator 7.96 49.85

Price Performance

Historical Comparison
MHO
SUPN

About MHO M/I Homes Inc.

M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprise a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Share on Social Networks: